Bradley Tokeshi, MD
Pulmonary Disease · Honolulu, HINPI 1417242462
Payments from drug & device makers
What this record shows
This record is dominated by education: $34,000 of the $40,881 with a category attached, or 83.2%. Intuitive Surgical accounts for 95.8% of it on its own, with 15 other manufacturers making up the rest. Among pulmonary disease clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 124 payments — averaging $329.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$39K
- GSK$743
- Philips North America LLC$242
- Siemens Medical Solutions USA, Inc.$186
- Optellum Ltd$150
- United Therapeutics Corporation$63
- plus $323 from 10 others
Across 1 payment — averaging $66,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Optellum Ltd$66K
What the payments were for
- Speaking & faculty fees$1,5004%
- Travel & lodging$2,0825%
- Food & beverage$3,2858%
- Education$34,00083%
- Gifts$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 41 | $39,173 |
| GSK | 53 | $743 |
| Philips North America LLC | 10 | $242 |
| Siemens Medical Solutions USA, Inc. | 2 | $186 |
| Optellum Ltd | 1 | $150 |
| United Therapeutics Corporation | 3 | $63 |
| AbbVie(2 entities) | 3 | $49 |
| Johnson & Johnson | 2 | $42 |
| Baxter Healthcare | 2 | $40 |
| Regeneron Healthcare Solutions, Inc. | 1 | $39 |
| Harmony Biosciences LLC | 1 | $38 |
| AstraZeneca | 1 | $26 |
| Pinnacle Biologics, Inc | 1 | $26 |
| Bayer | 1 | $22 |
| Olympus America Inc. | 1 | $21 |
| Galvanize Therapeutics, Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$20,655
- ION$18,000
- TRELEGY ELLIPTA$226
How this compares
$40,881 in reported general payments places this provider in the 95th percentile of 44 pulmonary disease providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 161 | $146,065 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 72 | $40,675 |
| Breo ElliptaFluticasone/Vilanterol | 31 | $15,406 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $7,369 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 223 | $5,892 |
| Wixela InhubFluticasone Propion/Salmeterol | 35 | $3,636 |
| Arnuity ElliptaFluticasone Furoate | 11 | $3,067 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $2,810 |
| Roflumilast | 15 | $1,342 |
| Ventolin HfaAlbuterol Sulfate | 18 | $968 |
| Omeprazole | 21 | $589 |
| Famotidine | 17 | $520 |
| Fluticasone Propionate | 16 | $300 |
| Prednisone | 30 | $85 |
| Azithromycin | 18 | $77 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $743 | $205,213275 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 44 pulmonary disease providers in Hawaii.
Other pulmonary disease in Honolulu
- Takkin LoHonolulu$324K
- Ernie YimHonolulu$20K
- Eric CrawleyHonolulu$17K
- Samuel EvansHonolulu$15K
- Ronson SatoHonolulu$14K
- Alvin FuruikeHonolulu$10K
- James YangHonolulu$8K
- Katsufumi NishidaHonolulu$8K
- Sheri Shimizu-SaitoHonolulu$8K
- Jennifer KayaHonolulu$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.